{"count": 15, "results": [{"_id": "37680878", "pmid": 37680878, "pmcid": "PMC10480553", "title": "Box Behnken optimization of cubosomes for enhancing the anticancer activity of metformin: Design, characterization, and in-vitro cell proliferation assay on MDA-MB-231 breast and LOVO colon cancer cell lines", "journal": "Int J Pharm X", "authors": ["Zaki RM", "Alkharashi LA", "Sarhan OM", "Almurshedi AS", "Aldosari BN", "Said M"], "date": "2023-08-25T00:00:00Z", "doi": "10.1016/j.ijpx.2023.100208", "meta_date_publication": "2023 Dec 15", "meta_volume": "6", "meta_issue": "", "meta_pages": "100208", "score": 50265.047, "text_hl": "This study aimed to formulate and statistically optimize cubosomal formulations of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MTF@@@) to enhance its @<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@breast@@@ anticancer activity. ", "citations": {"NLM": "Zaki RM, Alkharashi LA, Sarhan OM, Almurshedi AS, Aldosari BN, Said M. Box Behnken optimization of cubosomes for enhancing the anticancer activity of metformin: Design, characterization, and in-vitro cell proliferation assay on MDA-MB-231 breast and LOVO colon cancer cell lines Int J Pharm X. 2023 Dec 15;6():100208. PMID: 37680878", "BibTeX": "@article{37680878, title={Box Behnken optimization of cubosomes for enhancing the anticancer activity of metformin: Design, characterization, and in-vitro cell proliferation assay on MDA-MB-231 breast and LOVO colon cancer cell lines}, author={Zaki RM and Alkharashi LA and Sarhan OM and Almurshedi AS and Aldosari BN and Said M}, journal={Int J Pharm X}, volume={6}, pages={100208}}"}}, {"_id": "34867043", "pmid": 34867043, "pmcid": "PMC8626299", "title": "In vivo and in vitro studies evaluating the chemopreventive effect of metformin on the aryl hydrocarbon receptor-mediated breast carcinogenesis", "journal": "Saudi J Biol Sci", "authors": ["Alhoshani A", "Alotaibi M", "As Sobeai HM", "Alharbi N", "Alhazzani K", "Al-Dhfyan A", "Alanazi FE", "Korashy HM"], "date": "2021-12-01T00:00:00Z", "doi": "10.1016/j.sjbs.2021.08.051", "meta_date_publication": "2021 Dec", "meta_volume": "28", "meta_issue": "12", "meta_pages": "7396-7403", "score": 50257.66, "text_hl": "In vivo and in vitro studies evaluating the chemopreventive effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on the @GENE_AHR @GENE_196 @@@aryl hydrocarbon receptor@@@-mediated @<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@breast carcinogenesis@@@", "citations": {"NLM": "Alhoshani A, Alotaibi M, As Sobeai HM, Alharbi N, Alhazzani K, Al-Dhfyan A, Alanazi FE, Korashy HM. In vivo and in vitro studies evaluating the chemopreventive effect of metformin on the aryl hydrocarbon receptor-mediated breast carcinogenesis Saudi J Biol Sci. 2021 Dec;28(12):7396-7403. PMID: 34867043", "BibTeX": "@article{34867043, title={In vivo and in vitro studies evaluating the chemopreventive effect of metformin on the aryl hydrocarbon receptor-mediated breast carcinogenesis}, author={Alhoshani A and Alotaibi M and As Sobeai HM and Alharbi N and Alhazzani K and Al-Dhfyan A and Alanazi FE and Korashy HM}, journal={Saudi J Biol Sci}, volume={28}, number={12}, pages={7396-7403}}"}}, {"_id": "34753372", "pmid": 34753372, "title": "Perspectives of metformin use in endometrial cancer and other gynaecological malignancies.", "journal": "J Drug Target", "authors": ["Barczyński B", "Frąszczak K", "Kotarski J"], "date": "2022-04-01T00:00:00Z", "doi": "10.1080/1061186X.2021.2005072", "meta_date_publication": "2022 Apr", "meta_volume": "30", "meta_issue": "4", "meta_pages": "359-367", "score": 50250.285, "text_hl": "Finally, we present some most important clinical information regarding @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ efficacy in other @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@gynaecological malignancies@@@, mainly @<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@breast and ovarian cancer@@@.", "citations": {"NLM": "Barczyński B, Frąszczak K, Kotarski J. Perspectives of metformin use in endometrial cancer and other gynaecological malignancies. J Drug Target. 2022 Apr;30(4):359-367. PMID: 34753372", "BibTeX": "@article{34753372, title={Perspectives of metformin use in endometrial cancer and other gynaecological malignancies.}, author={Barczyński B and Frąszczak K and Kotarski J}, journal={J Drug Target}, volume={30}, number={4}, pages={359-367}}"}}, {"_id": "35267516", "pmid": 35267516, "pmcid": "PMC8909564", "title": "Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals", "journal": "Cancers (Basel)", "authors": ["Wang CH", "Huang CW", "Nguyen PA", "Lin MC", "Yeh CY", "Islam MM", "Rahmanti AR", "Yang HC"], "date": "2022-02-25T00:00:00Z", "doi": "10.3390/cancers14051211", "meta_date_publication": "2022 Feb 25", "meta_volume": "14", "meta_issue": "5", "meta_pages": "", "score": 50248.094, "text_hl": "Aspirin 21,691 (3.60) 92,676 (3.85)     3. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 16,380 (2.72) 58,131 (2.42)     4. ", "citations": {"NLM": "Wang CH, Huang CW, Nguyen PA, Lin MC, Yeh CY, Islam MM, Rahmanti AR, Yang HC. Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals Cancers (Basel). 2022 Feb 25;14(5):. PMID: 35267516", "BibTeX": "@article{35267516, title={Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals}, author={Wang CH and Huang CW and Nguyen PA and Lin MC and Yeh CY and Islam MM and Rahmanti AR and Yang HC}, journal={Cancers (Basel)}, volume={14}, number={5}}"}}, {"_id": "26405648", "pmid": 26405648, "title": "Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis.", "journal": "Curr Pharmacol Rep", "authors": ["Grossmann ME", "Yang DQ", "Guo Z", "Potter DA", "Cleary MP"], "date": "2015-04-01T00:00:00Z", "doi": "10.1007/s40495-015-0032-z", "meta_date_publication": "2015 Apr 1", "meta_volume": "1", "meta_issue": "5", "meta_pages": "312-323", "score": 50073.305, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Treatment for the Prevention and/or Treatment of @<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@Breast/Mammary Tumorigenesis@@@.", "citations": {"NLM": "Grossmann ME, Yang DQ, Guo Z, Potter DA, Cleary MP. Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis. Curr Pharmacol Rep. 2015 Apr 1;1(5):312-323. PMID: 26405648", "BibTeX": "@article{26405648, title={Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis.}, author={Grossmann ME and Yang DQ and Guo Z and Potter DA and Cleary MP}, journal={Curr Pharmacol Rep}, volume={1}, number={5}, pages={312-323}}"}}, {"_id": "28598826", "pmid": 28598826, "title": "The evaluation of the effect of metformin on breast fibrocystic disease.", "journal": "Breast Dis", "authors": ["Talaei A", "Moradi A", "Rafiei F"], "date": "2017-01-01T00:00:00Z", "doi": "10.3233/BD-160256", "meta_date_publication": "2017", "meta_volume": "37", "meta_issue": "2", "meta_pages": "49-53", "score": 50070.793, "text_hl": "The evaluation of the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@breast@@@ @DISEASE_Idiopathic_Pulmonary_Fibrosis @DISEASE_MESH:D054990 @@@fibrocystic disease@@@.", "citations": {"NLM": "Talaei A, Moradi A, Rafiei F. The evaluation of the effect of metformin on breast fibrocystic disease. Breast Dis. 2017;37(2):49-53. PMID: 28598826", "BibTeX": "@article{28598826, title={The evaluation of the effect of metformin on breast fibrocystic disease.}, author={Talaei A and Moradi A and Rafiei F}, journal={Breast Dis}, volume={37}, number={2}, pages={49-53}}"}}, {"_id": "21470407", "pmid": 21470407, "pmcid": "PMC3224599", "title": "Understanding the benefit of metformin use in cancer treatment", "journal": "BMC Med", "authors": ["Dowling RJ", "Goodwin PJ", "Stambolic V"], "date": "2011-04-06T00:00:00Z", "doi": "10.1186/1741-7015-9-33", "meta_date_publication": "2011 Apr 6", "meta_volume": "9", "meta_issue": "", "meta_pages": "33", "score": 50062.727, "text_hl": "The ability of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ to lower circulating @GENE_INS @GENE_3630 @@@insulin@@@ may be particularly important for the treatment of @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancers@@@ known to be associated with @DISEASE_Hyperinsulinism @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@, such as those of the @<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@breast and colon@@@. ", "citations": {"NLM": "Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment BMC Med. 2011 Apr 6;9():33. PMID: 21470407", "BibTeX": "@article{21470407, title={Understanding the benefit of metformin use in cancer treatment}, author={Dowling RJ and Goodwin PJ and Stambolic V}, journal={BMC Med}, volume={9}, pages={33}}"}}, {"_id": "28529619", "pmid": 28529619, "pmcid": "PMC5436259", "title": "Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines", "journal": "J Cancer", "authors": ["Kheder S", "Sisley K", "Hadad S", "Balasubramanian SP"], "date": "2017-04-09T00:00:00Z", "doi": "10.7150/jca.16584", "meta_date_publication": "2017", "meta_volume": "8", "meta_issue": "6", "meta_pages": "1053-1061", "score": 50054.96, "text_hl": "Some sub-types however have a poor prognosis. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@, an oral anti-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ drug is shown to have anti-@DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ effects in several types of @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ (@<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@breast, lung and ovarian cancer@@@). ", "citations": {"NLM": "Kheder S, Sisley K, Hadad S, Balasubramanian SP. Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines J Cancer. 2017;8(6):1053-1061. PMID: 28529619", "BibTeX": "@article{28529619, title={Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines}, author={Kheder S and Sisley K and Hadad S and Balasubramanian SP}, journal={J Cancer}, volume={8}, number={6}, pages={1053-1061}}"}}, {"_id": "24189334", "pmid": 24189334, "title": "Metformin use and endometrial cancer survival.", "journal": "Gynecol Oncol", "authors": ["Nevadunsky NS", "Van Arsdale A", "Strickler HD", "Moadel A", "Kaur G", "Frimer M", "Conroy E", "Goldberg GL", "Einstein MH"], "date": "2014-01-01T00:00:00Z", "doi": "10.1016/j.ygyno.2013.10.026", "meta_date_publication": "2014 Jan", "meta_volume": "132", "meta_issue": "1", "meta_pages": "236-40", "score": 50052.684, "text_hl": "Although greater progression free survival among @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@ovarian and breast cancers@@@ using @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has been reported, no studies have assessed the association of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use with survival in @SPECIES_9606 @@@women@@@ with @DISEASE_Endometrial_Neoplasms @DISEASE_MESH:D016889 @@@endometrial cancer@@@ (@DISEASE_Endometrial_Neoplasms @DISEASE_MESH:D016889 @@@EC@@@). ", "citations": {"NLM": "Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, Conroy E, Goldberg GL, Einstein MH. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014 Jan;132(1):236-40. PMID: 24189334", "BibTeX": "@article{24189334, title={Metformin use and endometrial cancer survival.}, author={Nevadunsky NS and Van Arsdale A and Strickler HD and Moadel A and Kaur G and Frimer M and Conroy E and Goldberg GL and Einstein MH}, journal={Gynecol Oncol}, volume={132}, number={1}, pages={236-40}}"}}, {"_id": "25056111", "pmid": 25056111, "pmcid": "PMC4108946", "title": "Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation", "journal": "Sci Rep", "authors": ["Hu T", "Chung YM", "Guan M", "Ma M", "Ma J", "Berek JS", "Hu MC"], "date": "2014-07-24T00:00:00Z", "doi": "10.1038/srep05810", "meta_date_publication": "2014 Jul 24", "meta_volume": "4", "meta_issue": "", "meta_pages": "5810", "score": 50052.625, "text_hl": "Reprogramming @<m>DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome</m> @DISEASE_MESH:D061325 @@@ovarian and breast cancer@@@ cells into non-cancerous cells by low-dose @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ or @CHEMICAL_Irinotecan @CHEMICAL_MESH:D000077146 @@@SN-38@@@ through @GENE_FOXO3 @GENE_2309 @@@FOXO3@@@ activation", "citations": {"NLM": "Hu T, Chung YM, Guan M, Ma M, Ma J, Berek JS, Hu MC. Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation Sci Rep. 2014 Jul 24;4():5810. PMID: 25056111", "BibTeX": "@article{25056111, title={Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation}, author={Hu T and Chung YM and Guan M and Ma M and Ma J and Berek JS and Hu MC}, journal={Sci Rep}, volume={4}, pages={5810}}"}}]}